|
Market Closed -
OTC Markets
19:20:45 07/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.7500 USD | +2.88% |
|
0.00% | -71.15% |
| 10-20 | 15 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange | FW |
| 10-15 | 14 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange | FW |
| Market Cap | 200M 20.23M 18.01M 16.69M 15.12M 28.42M 1.92B 28.9M 78.68M 1B 75.89M 74.32M 3.2B | P/E 2024 |
-2.97x | P/E 2025 | 1.63x |
|---|---|---|---|---|---|
| Enterprise Value | -221M -22.29M -19.84M -18.39M -16.66M -31.31M -2.11B -31.84M -86.67M -1.1B -83.6M -81.87M -3.52B | EV / Sales 2024 |
1.62x | EV / Sales 2025 | 23.8x |
| Free-Float |
78.37% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: Orexo AB
| 1 day | +2.88% | ||
| Current month | -31.82% | ||
| 1 month | -46.04% | ||
| 3 months | -58.33% | ||
| 6 months | -71.70% | ||
| Current year | -71.15% |
| 1 month | 0.73 |  | 1.26 |
| Current year | 0.73 | | 2.65 |
| 1 year | 0.73 | | 3 |
| 3 years | 0.73 | | 4.05 |
| 5 years | 0.73 | | 4.05 |
| 10 years | 0.73 | | 9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Nikolaj Sørensen
CEO | Chief Executive Officer | 54 | 04/02/2013 |
Fredrik Järrsten
DFI | Director of Finance/CFO | 59 | 31/08/2022 |
Jonas Savmarker
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 31/12/2001 | |
George Wilkinson
BRD | Director/Board Member | 70 | 10/04/2019 |
Christine Rankin
BRD | Director/Board Member | 62 | 31/03/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.88% | 0.00% | - | - | 21.49M | |
| +3.49% | +10.04% | +58.68% | +119.56% | 1,106B | |
| +2.19% | +4.32% | +33.88% | +69.52% | 612B | |
| +2.26% | +5.37% | +24.57% | +97.69% | 500B | |
| +2.58% | +8.37% | +38.71% | +63.14% | 367B | |
| +3.25% | +4.45% | +71.80% | +44.44% | 354B | |
| +1.85% | +6.04% | +21.47% | +49.17% | 286B | |
| +1.76% | +6.07% | +0.43% | +20.98% | 256B | |
| +3.29% | +6.32% | +44.71% | +57.43% | 230B | |
| +2.25% | +5.81% | +27.13% | +101.17% | 190B | |
| Average | +2.13% | +4.19% | +35.71% | +69.23% | 433.35B | |
| Weighted average by Cap. | +1.43% | +4.67% | +40.82% | +80.58% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 590M 59.6M 53.05M 49.17M 44.56M 83.74M 5.65B 85.14M 232M 2.95B 224M 219M 9.43B | 26M 2.63M 2.34M 2.17M 1.96M 3.69M 249M 3.75M 10.21M 130M 9.85M 9.65M 415M |
| Net income | -203M -20.51M -18.25M -16.92M -15.33M -28.81M -1.94B -29.29M -79.75M -1.02B -76.93M -75.33M -3.24B | 639M 64.59M 57.49M 53.28M 48.28M 90.73M 6.12B 92.25M 251M 3.2B 242M 237M 10.21B |
| Net Debt | 353M 35.63M 31.72M 29.39M 26.64M 50.06M 3.38B 50.9M 139M 1.77B 134M 131M 5.64B | -421M -42.52M -37.85M -35.08M -31.79M -59.74M -4.03B -60.74M -165M -2.11B -159M -156M -6.72B |
Employees
61
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ORX Stock
- ORXOY Stock
Select your edition
All financial news and data tailored to specific country editions
